Knockdown of Long Non-Coding RNA KCNQ1OT1 Restrained Glioma Cells’ Malignancy by Activating miR-370/CCNE2 Axis by Wei Gong et al.
ORIGINAL RESEARCH
published: 22 March 2017
doi: 10.3389/fncel.2017.00084
Knockdown of Long Non-Coding
RNA KCNQ1OT1 Restrained Glioma
Cells’ Malignancy by Activating
miR-370/CCNE2 Axis
Wei Gong1,2, Jian Zheng3,4, Xiaobai Liu3,4, Yunhui Liu3,4, Junqing Guo1,2, Yana Gao1,2,
Wei Tao 1,2, Jiajia Chen1,2, Zhiqing Li1,2, Jun Ma1,2 and Yixue Xue1,2*
1Department of Neurobiology, College of Basic Medicine, China Medical University, Shenyang, China, 2Key Laboratory of Cell
Biology, Ministry of Public Health of China, Key Laboratory of Medical Cell Biology, Ministry of Education of China, China
Medical University, Shenyang, China, 3Department of Neurosurgery, Shengjing Hospital of China Medical University,
Shenyang, China, 4Liaoning Research Center for Translational Medicine in Nervous System Disease, Shenyang, China
Edited by:
James Francis Curtin,










Received: 14 November 2016
Accepted: 10 March 2017
Published: 22 March 2017
Citation:
Gong W, Zheng J, Liu X, Liu Y, Guo J,
Gao Y, Tao W, Chen J, Li Z, Ma J and
Xue Y (2017) Knockdown of Long
Non-Coding RNA
KCNQ1OT1 Restrained Glioma Cells’
Malignancy by Activating
miR-370/CCNE2 Axis.
Front. Cell. Neurosci. 11:84.
doi: 10.3389/fncel.2017.00084
Accumulating evidence has highlighted the potential role of long non-coding RNAs
(lncRNAs) as biomarkers and therapeutic targets in solid tumors. Here, we elucidated
the function and possible molecular mechanisms of lncRNA KCNQ1OT1 in human
glioma U87 and U251 cells. Quantitative Real-Time polymerase chain reaction (qRT-
PCR) demonstrated that KCNQ1OT1 expression was up-regulated in glioma tissues
and cells. Knockdown of KCNQ1OT1 exerted tumor-suppressive function in glioma
cells. Moreover, a binding region was confirmed between KCNQ1OT1 and miR-370 by
dual-luciferase assays. qRT-PCR showed that miR-370 was down-regulated in human
glioma tissue and cells. In addition, restoration of miR-370 exerted tumor-suppressive
function via inhibiting cell proliferation, migration and invasion, while promoting the
apoptosis of human glioma cells. Knockdown of KCNQ1OT1 decreased the expression
level of Cyclin E2 (CCNE2) by binding to miR-370. Further, miR-370 bound to CCNE2
3′UTR region and decreased the expression of CCNE2. These results provided a
comprehensive analysis of KCNQ1OT1-miR-370-CCNE2 axis in human glioma cells and
might provide a novel strategy for glioma treatment.
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INTRODUCTION
Gliomas are one of the most life-threatening and common primary human brain malignancies
with an annual incidence of five cases per 100,000 people. Despite advancements in surgery and
adjuvant therapy, the prognosis remains very poor, with a median survival of less than 15 months
(Xu et al., 2010; Li et al., 2014).
Long non-coding RNAs (lncRNAs) have been confirmed to act as key molecules in cancer
development and progression (Cloutier et al., 2016; Liu et al., 2016). Dysregulations of lncRNAs
are discovered in various tumor tissues and cancer cells where they serve as oncogenes or
tumor suppressors (Ellinger et al., 2015; Jiang et al., 2016). KCNQ1OT1, an imprinted antisense
lncRNA in the human KCNQ1 locus on chromosome 11p15.5, is involved in cis-limited
silencing within an imprinted KCNQ1 cluster (Zhang et al., 2014; Sunamura et al., 2016). Earlier
studies showed that KCNQ1OT1 was up-regulated in breast cancer and conferred to breast cancer
Frontiers in Cellular Neuroscience | www.frontiersin.org 1 March 2017 | Volume 11 | Article 84
Gong et al. KCNQ1OT1 Inhibition Restrained Glioma Malignancy
malignancy (Zhang et al., 2016a). Similarly, over-expressed
KCNQ1OT1 contributed to the carcinogenesis of hepatocellular
carcinoma (Wan et al., 2013). However, the expression and
function of KCNQ1OT1 in glioma remain unclear.
MicroRNAs (miRNAs) play crucial roles in
post-transcriptional gene regulation and serve as negative
gene regulators by targeting 3′-UTR of downstream genes
(Karsy et al., 2012). MiRNAs have emerged as key regulators
in cancer cell biology including cell proliferation, migration,
invasion and apoptosis (Zhao et al., 2015). Aberrant expression
of miR-370 has been reported in various cancers. In most cases,
miR-370 serves as a tumor-suppressive gene in tumors such as
liver cancer and osteosarcoma (Duan et al., 2015; Sun G. et al.,
2016). More importantly, miR-370 has been confirmed to be
down-regulated in glioma and reduces glioma cells growth (Peng
et al., 2016). But the detailed function of miR-370 still needs to
be explored.
Cyclin E2 (CCNE2) is a member of cyclin E family, and
one of its major function is making transition from G0/G1 to S
phase through binding with CDK2 and phosphorylation of Rb
protein (Bizama et al., 2014; Ng et al., 2014; Cong et al., 2015).
CCNE2 expression was found to be dysregulated inmany cancers
such as breast cancer and thyroid cancer (Payton et al., 2002;
Liang et al., 2015). However, the characterization of CCNE2 in
glioma has not been investigated.
In the present study, we investigated the expression and
function of KCNQ1OT1, miR-370 and CCNE2 in glioma tissues
and cells. We also studied the underlying interactions among
them. There was a specific binding site between KCNQ1OT1 and
miR-370. KCNQ1OT1 and miR-370 negatively regulated their
respective expression. MiR-370 targeted CCNE2 3′-UTR and
impaired its expression. We hypothesized KCNQ1OT1/miR-
370/CCNE2 might exert crucial function in glioma cells
progression and might be a novel therapeutic target.
MATERIALS AND METHODS
Clinical Tumors
All human glioma tumors and normal brain tumors (NBTs)
were collected from the Department of Neurosurgery, Shengjing
Hospital of China Medical University, from 2013 to 2016.
Glioma samples were divided into four groups: Grade I, Grade
II, Grade III and Grade IV, according to the World Health
Organization (WHO) classification. Informed consent was
obtained from all patients and the study procedure was approved
by Research Ethics Board at the Shengjing Hospital of China
Medical University. The tumor specimens were immediately
frozen and preserved in liquid nitrogen until used in our
research.
Cell Culture
Human glioma cell lines (U87, U251) and human embryonic
kidney (HEK) 293T cells were acquired from Shanghai Institutes
for Biological Sciences Cell Resource Center. They were cultured
in high glucose Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS, Gibco,
Carlsbad, CA, USA). Primary normal human astrocytes (NHA)
were obtained from Sciencell Research Laboratories (Carlsbad,
CA, USA) and cultured in astrocyte medium (Carlsbad, CA,
USA). All cells were incubated at 37◦C a humidified incubator
with 5% CO2.
RNA Extraction and Quantitative
Real-Time PCR (qRT-PCR)
We used trizol reagent (Life Technologies Corporation,
Carlsbad, CA, USA ) extracted total RNA from NBTs, glioma
tissues, NHA, U87 and U251 cell lines. The primers for
KCNQ1OT1 and GAPDH were synthesized from Takara Bio
(Japan). The primers for miR-370 and U6 were synthesized
from the Applied Biosystems. RNA concentration and
quality were measured by the 260/280 nm ratio using
a Nanodrop Spectrophotometer (ND-100, and we used
One-Step SYBR PrimeScript RT-PCR Kit (Perfect Real
Time; Takara Bio, Inc., Japan) to test the expression of
KCNQ1OT1 in NBTs, glioma tissues, NHA, U87 and U251 cells.
KCNQ1OT1: forward 5′-TGCAGAAGACAGGACACTGG-
3′, reverse 5′-CTTTGGTGGGAAAGGACAGA-3′; GAPDH:
forward 5′-TGCACCACCAACTGCTTAGC-3′, reverse 5′-
GGCATGCACTGTGGTCATGAG-3′. GAPDH was used as
endogenous controls for genes expressions. High Capacity
cDNA Reverse Transcription Kits (Applied Biosystems, Foster
City, CA, USA) and Taqman Universal Master Mix II (Life
Technologies Corporation, Carlsbad, CA, USA) were used to
examine the expression levels of miR-370 and U6 (Applied
Biosystems, Foster City, CA, USA) levels. Fold change was
calculated as 2−∆∆Ct in gene expression.
Cell Transfections
Short-hairpin KCNQ1OT1 (sh-KCNQ1OT1) plasmid and its
respective non-targeting sequence (negative control, sh-NC),
miR-370 agomir (pre-miR-370), miR-370 antagomir (anti-miR-
370) and their respective non-targeting sequence (negative
control, NC; pre-NC or anti-NC) were synthesized as previously
described (GenePharma, Shanghai, China; Zhou et al., 2009;
Wang and Li, 2010; Wang et al., 2012). CCNE2 full length
(with 3′UTR) plasmid, CCNE2 (without 3′UTR) plasmid and
their respective non-targeting sequence (negative control, NC)
were synthesized as previously described (Life technology,
Waltham, MA, USA; Pleet et al., 2016). We used Opti-MEM
and Lipofectamine 3000 reagent (Life Technologies Corporation,
Carlsbad, CA, USA) for transfection when cells were at
50%–70% confluence. Stable cell lines were obtained through
the selection by means of Geneticin (G418; Sigma-Aldrich,
St. Louis, MO, USA), G418-resistant clones were obtained
after 3–4 weeks. We used qRT-PCR to detect the knockdown
efficiency.
Cell Proliferation Assay
After knockdown efficacy was confirmed, cell counting Kit-8
(CCK-8, Dojin, Japan) assay was used for cell proliferation. Two-
thousand cells were seeded per well in 96-well plates at a same
density, and 10 µL of Cell Counting Kit-8 was added into each
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well after 48 h. Then incubated at 37◦C for 2 h and absorbance
was measured at 450 nm.
Apoptosis Detection
Apoptosis was evaluated using Annexin V-PE/7-AAD staining
apoptosis detection kit (Southern Biotech, Birmingham, AL,
USA) according to the manufacturer’s instructions. After the
cells washed two times with 4◦C PBS, cells were collected and
stained with Annexin V-PE and 7-AAD. Then acquired the cells
by flow cytometry (FACScan, BD Biosciences, San Jose, CA,
USA) and analyzed by CELL Quest 3.0 software.
Cell Migration and Invasion Assay
The abilities of cell migration and invasion were tested using the
24-well transwell chambers with 8 µm pore size polycarbonate
membrane (Corning, NY, USA). For cell invasion assay, the
filter was pre-coated with 500 ng/ml matrigel solution (BD,
Franklin Lakes, NJ, USA) and incubated at 37◦C for 4 h
before the invasion assay started; placed 500 µL of 10% FBS
medium in the lower chamber, and placed 100 µL serum-free
medium in the upper chamber. After incubation at 37◦C for
24 h, the cells on the upper membrane surface were scraped
off. Surface were fixed with methanol and glacial acetic acid
30 min and then stained with 10% Giemsa solution. Number
of cells was counted, and five randomly fields were counted
randomly in each well. The photographs were taken at 200×
magnification.
Luciferase Reporter Assays
KCNQ1OT1 full length and CCNE2 3′-UTR sequences were
amplified by PCR and cloned into a pmirGlo Dual-luciferase
miRNA Target Expression Vector (Promega, Madison, WI,
USA) to construct luciferase reporter vector (KCNQ1OT-
Wt and CCNE2-Wt; GenePharma). The sequence of putative
binding site was replaced as indicated (KCNQ1OT1-Mut
and CCNE2-Mut) to mutate the putative binding sites of
KCNQ1OT1 or CCNE2. HEK-293T cells were seeded in 96-well
plates and the cells were co-transfected with KCNQ1OT1-Wt
(or KCNQ1OT1-Mut) or CCNE2-Wt (or CCNE2-Mut) and
miR-370 or miR-370-NC plasmids when they reached 50%–70%
confluence. The luciferase activities were measured at 48 h after
transfection by Dual-Luciferase reporter assay kit (Promega).
The cells were divided in five groups respectively: control
group, KCNQ1OT1-Wt + miR-370-NC (transfected with
KCNQ1OT1-Wt and pre-NC), KCNQ1OT1-Wt + miR-370
group (transfected with KCNQ1OT1-Wt and pre-miR-370),
KCNQ1OT1-Mut + miR-370-NC group (transfected with
KCNQ1OT1-Mut and pre-NC), KCNQ1OT1-Mut + miR-370
group (transfected with KCNQ1OT1-Mut and pre-miR-370);
Control group, CCNE2-Wt + miR-370-NC (transfected with
CCNE2-Wt and pre-NC), CCNE2-Wt + miR-370 group
(transfected with CCNE2-Wt and pre-miR-370), CCNE2-Mut +
miR-370-NC group (transfected with CCNE2-Mut and pre-NC),
CCNE2-Mut + miR-370 group (transfected with CCNE2-Mut
and pre-miR-370).
RNA Immunoprecipitation
RNA immunoprecipitation was performed as previously
reported (Zheng et al., 2016). Briefly, to explore whether
KCNQ1OT1 and miR-370 were associated with the RISC,
we performed RNA immunoprecipitation. Glioma cells were
lysed in complete RNA lysis buffer with protease inhibitor and
RNase inhibitor from an EZ-Magna RIP RNA-binding protein
immunoprecipitation kit (Millipore, Billerica, MA, USA). Whole
cell lysates from the control groups and miR-370 groups were
incubated with RIP immunoprecipitation buffer containing
magnetic beads conjugated with human anti-Argonaute
2 antibody (Millipore, Billerica, MA, USA) and the negative
control (normal mouse IgG; Millipore, Billerica, MA, USA).
Samples were incubated with Proteinase K buffer, and then
the immunoprecipitated RNA was isolated. Purified RNA
was obtained and qRT-PCR was performed with the primers
mentioned above to illustrate the presence of the binding targets.
Western Blot Analysis
Total protein of cells were lysed using ice-cold RIPA (Beyotime
Institute of Biotechnology) buffer supplemented with protease
inhibitors and centrifuged at 17,000× g 4◦C for 40 min. Equal
amount of total cell lysate protein samples (40 µg) went
electrophoresis in sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and then Equal amount of total
cell lysate protein samples (40 µg) went electrophoresis in
SDS-PAGE and then transferred to polyvinylidene difluoride
membranes. Membranes were incubated in 5% nonfat milk
dissolved in Tris-buffered saline (TBS) containing 0.1%
Tween-20 for 2 h at room temperature. After blocking of
non-specific bindings, the protein went immunoblotting
with primary antibodies against CCNE2 (1:200, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), YAP1 (1:1000, Santa
Cruz Biotechnology, Santa Cruz, CA, USA), p-YAP (1:2000,
CST, USA) and GAPDH (1:1000, Proteintech, Chicago, IL,
USA). Followed by incubation with appropriate correlated
HRP-conjugated secondary antibody, then the membranes were
incubated with secondary antibodies (goat anti-rabbit or goat
anti-mouse, 1:5000 respectively; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) at room temperature for 2 h. Immunoblots
were visualized by enhanced chemiluminescence (ECL kit, Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and scanned using
ChemImager 5500 V2.03 software. The integrated density values
(IDV) were calculated using FluorChem 2.0 software.
Subcutaneous and Orthotopic Xenografts
in Nude Mice
The stably transfected human glioma tissues were used in
the in vivo study. Four-week-old male nude mice were
purchased from the National Laboratory Animal Center
(Beijing, China). All mice were free to autoclaved food and
water during the experiment, and all experiments with nude
mice were performed strictly in accordance with a protocol
approved by the Administrative Panel on Laboratory Animal
Care of the China Medical University. Lentivirus encoding
miR-370 was generated using pLenti6.3/V5eDEST Gateway
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Vector Kit (Life Technologies Corporation, Carlsbad, CA,
USA). The miR-370 and short-hairpin RNA targeting human
KCNQ1OT1 were ligated into the pLenti6.3/V5eDEST vector
and LV3-CMV-GFP-Puro vector (GenePharma, Shanghai,
China), respectively, and then pLenti6.3/V5eDEST-miR-370 and
LV3-CMV-GFPPuro-sh-KCNQ1OT1 vectors were generated.
The ViraPower PackagingMix was used to generate Lentivirus in
293FT cells. After infection, the stable expressing cells of miR-370
and sh-KCNQ1OT1 were obtained. The lentiviruses of miR-370
were transduced in sh-KCNQ1OT1 stably transfected cells to
generate miR-370 + sh-KCNQ1OT1 cells. The nude mice were
divided into four groups: control group (only U87 or U251),
sh-KCNQ1OT1 group (sh-KCNQ1OT1 stable expression U87 or
U251 cells), miR-370 group (miR-370 stable over-expression
U87 or U251 cells) and sh-KCNQ1OT1 + miR-370 group
(KCNQ1OT1 inhibition and miR-370 over-expression stable
U87 and U251 cells). 3 × 105 cells were subcutaneously
injected in the right flanks of the mice. Tumor volume was
measured every 4 days when the tumors were obviously
identified and the volume was calculated by the formula:
volume (mm3) = length × width2/2. Fourty-four days after
injection, mice were sacrificed and tumors were isolated. As
previously described (Rubin et al., 2003; Zhou et al., 2015), for
survival analysis in orthotopic inoculations, 3 × 105 cells were
stereotactically implanted into the right striatum of the mice in
the position of 2 mm posterior to the bregma, 2 mm laterally, and
2 mm deep to the dura. The number of survived nude mice was
marked and survival analysis was investigated using Kaplane-
Meier survival curve.
Statistical Analysis
Data are presented as mean ± standard deviation (SD). SPSS
18.0 statistical software with the Student’s t-test or one-way
analysis of variance (ANOVA) were used to evaluate all
statistical analyses. Multiple comparison between the groups was
performed using S-N-K method. Differences were considered to
be significant when P < 0.05.
RESULTS
KCNQ1OT1 was Up-Regulated in Glioma
Tissues and Cell Lines,
KCNQ1OT1 Inhibition Impeded Glioma
Cells Malignant Progression
The latest studies confirmed aberrant KCNQ1OT1 expression
was ubiquitous in various tumors. We first investigated
KCNQ1OT1 expression in glioma tissues and cells. As
Figures 1A,B showed, the expression of KCNQ1OT1 in glioma
tissues and cell lines was robustly up-regulated in glioma
tissues (P < 0.01), U87 and U251 cells (P < 0.05), and
was positively correlated with the histopathological grades
of gliomas. Therefore, we hypothesized KCNQ1OT1 might
contribute to glioma cells’ malignancy. U87 and U251 cells
with stable inhibition of KCNQ1OT1 were established. We then
examined the knockdown efficiency (Figure 1C; P < 0.01).
As expected, cell proliferation was reduced in sh-KCNQ1OT1
group compared with sh-NC group (Figure 1D; P < 0.05).
Similarly, flow cytometry results showed that down-regulation
of KCNO1OT1 induced glioma cells apoptosis compared with
sh-NC group (Figure 1E; P < 0.05). Further, as shown in
Figure 1F, U87 and U251 cells’ migration and invasion ability
were weaker in experiment group compared with sh-NC group
(P < 0.05). These results indicate KCNQ1OT1 acts as an
oncogene in glioma cells.
Over-Expression of miR-370 Impaired Cell
Proliferation, Migration and Invasion, While
Promoted Apoptosis of Glioma Cells
An earlier study has shown miR-370 was down-regulated in
glioma tissues and cells (Peng et al., 2016). In addition, the
restoration of miR-370 reduced glioma cells proliferation. We
further explored miR-370’s detailed function in glioma cells.
Consistent with previously reported, CCK-8 assay indicated
over-expression of miR-370 restrained the proliferation of
U87 and U251 cells compared with pre-NC group at different
times (Figure 2A; P < 0.05). Meanwhile, over-expression of
miR-370 led to an increased ratio in apoptosis compared with
pre-NC group (Figure 2B; P < 0.05). Transwell assays were
conducted to assess the effects of miR-370 on the migratory
and invasive abilities of glioma cells. As Figure 2C showed, the
number of cells was reduced in pre-miR-370 group compared
with pre-NC group (P< 0.05). Therefore miR-370 might act as a
tumor suppressor in glioma cells.
MiR-370 Mediated the Tumor-Suppressive
Effect of KCNQ1OT1’s Inhibition on Glioma
Cells
Multiple studies have confirmed lncRNAs harbor miRNAs
binding sites (Su et al., 2016). LncRNAs can sponge miRNAs
in a sequence-specific manner (Ballantyne et al., 2016). In most
cases, lncRNAs and miRNAs regulate expression respectively
in an Argonaute2-dependent manner (Kobayashi and Tomari,
2016). We used a bioinformatics database (Starbase) to infer
the potential targets of miR-370. KCNQ1OT1 was identified
as a potential target and harbored one putative binding site
of miR-370. We first examined the expression of miR-370 in
KCNQ1OT1 inhibition glioma cells. As shown in Figure 3A,
miR-370 expression was increased in sh-KCNQ1OT1 group
compared with sh-NC group (P < 0.01). Further, as shown in
Figure 3A, we found KCNQ1OT1 expression was negatively
correlated with miR-370 expression in glioma cells (P < 0.01).
Luciferase assays were used to confirm the functional binding
site between KCNQ1OT1 and miR-370. The binding site
and the designed mutated site are shown in Figure 3B.
As shown in Figure 3C, luciferase activity was significantly
reduced in KCNQ1OT1-WT + miR-370 group compared with
KCNQ1OT1-WT + miR-370-NC group (P < 0.05). We further
performed RNA-binding protein immunoprecipitation (RIP)
experiment to ascertain whether KCNQ1OT1 and miR-370 were
in a RNA-induced silencing complex (RISC). As shown in
Figure 3D, KCNQ1OT1 and miR-370 were both detected in
anti-Ago2 group (P < 0.01). These results demonstrated an
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FIGURE 1 | KCNQ1OT1 expression in glioma tissues and human glioma cells. Knockdown of KCNQ1OT1 restrained cell proliferation, promoted apoptosis
and restrained migration and invasion in human glioma cells. (A) KCNQ1OT1 expression in normal brain tissues (NBTs), different grades of human glioma tissues.
Data are presented as the mean ± standard deviation (SD; n = 15, each group). ∗P < 0.01 vs. NBTs group. (B) Expression levels of KCNQ1OT1 in human normal
astrocytes and human glioma cell lines U87 and U251. Data are presented as the mean ± SD (n = 5, each group). ∗P < 0.01 vs. Normal human astrocytes (NHA)
group. (C) Knockdown efficiency of KCNQ1OT1 inhibition. (D) CCK-8 assay was used to determine the proliferation effect of KCNQ1OT1 on human glioma cells.
(E) Flow cytometry analysis of KCNQ1OT1 knockdown on glioma cells. (F) Quantification of migration and invasion of KCNQ1OT1 knockdown of human glioma
cells. Representative images and accompanying statistical plots were presented. Data are presented as the mean ± SD (n = 5, each group). ∗P < 0.05 vs. sh-NC
group. Scale bars represent 20 µm. ∗∗P < 0.01 vs. NBTs group.
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FIGURE 2 | Effect of miR-370 on proliferation, migration, invasion and apoptosis of human glioma cells. (A) Cell counting Kit-8 (CCK-8) assay was used to
determine the proliferation effect of miR-370 on human glioma cells at 24 h, 48 h and 72 h. (B) Flow cytometry analysis of human glioma cells with the expression of
miR-370 changed. (C) Quantification of migration and invasion cells with the expression of miR-370 changed. Representative images and accompanying statistical
plots were presented. Data are presented as the mean ± SD (n = 5, each group). ∗P < 0.05 vs. pre-NC group; #P < 0.05 vs. anti-NC group. Scale bars represent
20 µm.
insight into the mechanism of KCNQ1OT1 negatively regulating
miR-370.
To determine whether miR-370 conferred to the tumor-
suppressive effect of KCNQ1OT1’s inhibition, we transfected
over-expression of miR-370 or miR-370 inhibitors into the stable
sh-KCNQ1OT1 cells prior to the assessment of cell proliferation,
apoptosis, migration and invasion. As shown in Figure 3E,
sh-KCNQ1OT1 cells co-transfected with over-expression of
miR-370 had the strongest inhibitory effect on cell proliferation
compared with sh-NC + pre-NC group at different times
(P < 0.05). Flow cytometry results showed that glioma
cells treated with sh-KCNQ1OT1 + pre-miR-370 exhibited
increased apoptotic ratio compared with sh-NC + pre-NC
group (Figure 3F; P < 0.05). Similarly, knockdown of
KCNQ1OT1 combined with restoration of miR-370 robustly
decreased migrating and invading glioma cells (Figure 3G;
P < 0.05).
CCNE2 was Involved in
KCNQ1OT1/miR-370-Mediated Glioma
Cells Malignant Progression
CCNE2 exerts oncogenetic function in various tumors such
as breast cancer and bladder cancer (Gupta et al., 2016). We
first detected the expression of CCNE2 in glioma tissues using
western blot. As shown in Figure 4A, CCNE2 expression
were obviously up-regulated in high- and low-grade glioma
tissues compared with normal brain tissues (NBTs; P < 0.05).
CCNE2 was identified as one of the downstream genes of
miR-370 by Bioinformatics database (Targetscan, miRanda and
Starbase). Luciferase reporter assay was performed to verify the
putative binding site between miR-370 and CCNE2. The binding
site and the designed mutated site are shown in Figure 4B. As
shown in Figure 4C, luciferase activity was significantly reduced
in CCNE2-Wt + miR-370 group compared with CCNE2-Wt +
miR-370-NC group (P < 0.05).
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FIGURE 3 | MiR-370 targeted KCNQ1OT1 and its expression was negatively correlative with KCNQ1OT1, miR-370 was involved in
KCNQ1OT1-mediated regulation of human glioma cells. (A) Quantitative Real-Time polymerase chain reaction (qRT-PCR) analysis for miR-370 expression
negatively correlative with KCNQ1OT1 in human glioma cell lines. Data are presented as the mean ± SD (n = 5, each group). ∗∗P < 0.01 vs. sh-NC group.
∗∗P < 0.01 vs. pre-NC; ##P < 0.01 vs. sh-NC group. (B) KCNQ1OT1 harbored a putative miR-370 binding site, and designed mutant sequences were indicated.
(C) Dual-luciferase reporter assay of human embryonic
(Continued)
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FIGURE 3 | Continued
kidney (HEK) 293T cells co-transfected with KCNQ1OT1-WT and
miR-370-NC or KCNQ1OT1-WT and miR-370, and KCNQ1OT1-Mut and
miR-370-NC or KCNQ1OT1-Mut and miR-370. Data are presented as the
mean ± SD (n = 5, each group). ∗P < 0.05 vs. KCNQ1OT1-WT +
miR-370-NC group. (D) MiR-370 was identified in KCNQ1OT1-RISC complex.
KCNQ1OT1 and miR-370 expression levels were measured using qRT-PCR
(Data represent mean ± SD (n = 5, each group). &&P < 0.01 vs. anti-normal
IgG group. (E) CCK-8 assay was used to evaluate the effect of
KCNQ1OT1 and miR-370 on cell proliferation in human glioma cells at 24 h,
48 h and 72 h. Data are presented as the mean ± SD (n = 5, each group).
∗P < 0.05 vs. sh-NC + pre-NC group. (F) Flow cytometry analysis was used
to evaluate the effect of KCNQ1OT1 and miR-370 on cell apoptosis in human
glioma cells. Data are presented as the mean ± SD (n = 5, each group).
∗P < 0.05 vs. sh-NC + pre-NC group. (G) Quantification of cells to evaluate
the effect of KCNQ1OT1 and miR-370 on cell migration and invasion in human
glioma cells. Data are presented as the mean ± SD (n = 5, each group).
∗P < 0.05 vs. sh-NC + pre-NC group. Scale bars represent 20 µm.
Further, we examined the expression of CCNE2 protein
in cells treated with KCNQ1OT1 or miR-370. As shown
in Figure 4D, CCNE2 protein level was decreased in
sh-KCNQ1OT1 group compared with sh-NC group (P < 0.05).
CCNE2 protein levels were also examined in overexpressed or
inhibited miR-370 cells. As expected, CCNE2 protein level was
attenuated in pre-miR-370 group, while it was up-regulated in
anti-miR-370 group (Figure 4E; P < 0.05). Having confirmed
both KCNQ1OT1 and miR-370 affected glioma cells’ malignant
biological behaviors, we further investigated the underlying
molecular mechanisms. Figure 4F showed that CCNE2 protein
expression was robustly decreased in sh-KCNQ1OT1 + pre-
miR-370 group, while anti-miR-370 rescued sh-KCNQ1OT1
induced down-regulation of CCNE2 protein expression
(P < 0.05).
CCNE2 Promoted Cell Proliferation,
Migration and Invasion, While Inhibited
Apoptosis of Glioma Cells
Having confirmed CCNE2 was up-regulated in glioma cells and
participated in KCNQ1OT1/miR-370 regulating glioma cells’
malignancy, we examined the effect of CCNE2 on glioma cells’
biological behaviors. CCK-8 assay indicated over-expression of
CCNE2 (CCNE2 (+)) promoted the proliferation of glioma
U87 and U251 cells compared with CCNE2 (+)-NC group
(Figure 5A; P < 0.05). Meanwhile, over-expression of CCNE2
(CCNE2 (+)) led to a decreased apoptotic ratio of glioma cells
compared with CCNE2 (+)-NC group (Figure 5B; P < 0.05).
Transwell assays were conducted to assess the effects of CCNE2
(+) on the migratory and invasive ability of glioma cells.
As expected, the migratory and invasive ability was stronger
in CCNE2 (+) group compared with CCNE2 (+)-NC group
(Figure 5C; P < 0.05).
CCNE2 Reversed KCNQ1OT1 Knockdown
Phenotype
To investigate whether over-expression of CCNE2 reversed
KCNQ1OT1 knockdown phenotype, cells expressed
sh-KCNQ1OT1 + CCNE2 were established. CCK-8 assay
showed that over-expression of CCNE2 reversed inhibitory of
proliferation sh-KCNQ1OT1 induced (Figure 6A; P < 0.05).
Further, over-expression of CCNE2 rescued increased apoptotic
ratio sh-KCNQ1OT1 induced of glioma cells (Figure 6B;
P < 0.05). Meanwhile, Figure 6C showed that over-expression
of CCNE2 reversed inhibitory of migratory and invasive ability
sh-KCNQ1OT1 induced of glioma cells.
Reintroduction of miR-370 Impaired
CCNE2-Induced Promotion Effects on
Glioma U87 and U251 Cells by Targeting
CCNE2 3′-UTR
To discover whether CCNE2 reversed miR-370-mediated
blocking of glioma U87 and U251 cells’ malignant evolution in a
sequence-specific manner, we analyzed proliferation, migration,
invasion and apoptosis of U87 and U251 which stably expressed
miR-370 + CCNE2 (non-3′UTR). The proliferation of glioma
cells in miR-370 + CCNE2 (non-3′UTR) group was significantly
rescued compared with miR-370 + CCNE2 group at different
times (Figure 7A; P < 0.05). Cells treated with miR-370 +
CCNE2 (non-3′UTR) exhibited a vigorously reduced apoptotic
ratio in U87 and U251 cells compared with miR-370 +
CCNE2 group (Figure 7B; P < 0.05). Moreover, Figure 7C
showed that the number of migrating and invading cells were
increased in miR-370 + CCNE2 (non-3′UTR) group compared
with miR-370 + CCNE2 group (P < 0.05).
A latest study showed CCNE2 promoted breast cancer cells’
malignant progression via activating Hippo pathway (Pegoraro
et al., 2015). Therefore, we detected p-YAP and YES-associated
protein (YAP) expression in cells treated with KCNQ1OT1 and
miR-370. As shown in Figure 7D, p-YAP expression was
up-regulated in sh-KCNQ1OT1 group and pre-miR-370 group
compared with control group (P < 0.05). Besides, p-YAP
expression was robustly increased in sh-KCNQ1OT1 + pre-miR-
370 group.
KCNQ1OT1 Inhibition Combined with
miR-370 Over-Expression Significantly
Reduced Tumor Growth In Vivo
As shown in Figures 8A,B, knockdown of KCNQ1OT1 or
over-expression of miR-370 reduced tumor growth.
Further, knockdown of KCNQ1OT1 combined with
over-expression of miR-370 exhibited the smallest tumor
compared with each group in the experiment (P < 0.05).
Similarly, the survival analysis demonstrated both
KCNQ1OT1 inhibition and miR-370 restoration prolonged
survival period compared with control group, and as
expected, KCNQ1OT1 inhibition combined with miR-370
reintroduction contributed to the longest survival period
(Figure 8C).
DISCUSSION
In this study, we demonstrated KCNQ1OT1 was up-regulated in
glioma tissues and cells. Knockdown of KCNQ1OT1 suppressed
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FIGURE 4 | Cyclin E2 (CCNE2) was up-regulated in glioma tissues. CCNE2 was a target of miR-370, both KCNQ1OT1 and miR-370 could modulate
CCNE2 expression. (A) CCNE2 protein expression levels in normal brain tissues and glioma tissues using GAPDH as an endogenous control. Representative protein
expression and their integrated light density values (IDVs) of CCNE2 in normal brain tissues, low-grade glioma tissues ([WHO] I-II), and high-grade glioma tissues
([WHO] III-IV) are shown. Data are presented as the mean ± SD (n = 5, each group). ∗P < 0.05 vs. NBTs group. (B) CCNE2 harbored a putative miR-370 binding
site, and designed mutant sequences were indicated. (C) Dual-luciferase reporter assay of HEK 293T cells co-transfected with CCNE2-Wt and miR-370-NC or
CCNE2-Wt and miR-370, and CCNE2-Mut and miR-370-NC or CCNE2-Mut and miR-370. Data are presented as the mean ± SD (n = 5, each group). ∗P < 0.05 vs.
CCNE2-Wt + miR-370-NC group. (D) Western blot analysis for CCNE2 in KCNQ1OT1 knockdown of human glioma cells using GAPDH as an endogenous control.
Data are presented as the mean ± SD (n = 5, each group). ∗P < 0.05 vs. sh-NC group. (E) Western blot analysis for CCNE2 in miR-370 over-expression and
miR-370 inhibition of human glioma cells using GAPDH as an endogenous control. Data are presented as the mean ± SD (n = 5, each group). ∗P < 0.05 vs. pre-NC
group; #P < 0.05 vs. anti-NC group. (F) Western blot analysis for CCNE2 in co-transfected KCNQ1OT1 inhibition with miR-370 over-expression or miR-370 inhibition
of human glioma cells using GAPDH as an endogenous control. Data are presented as the mean ± SD (n = 5, each group). ∗P < 0.05 vs. sh-NC + pre-NC group.
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FIGURE 5 | Effect of CCNE2 on proliferation, migration, invasion and apoptosis of human glioma cells. (A) CCK-8 assay was used to determine the
proliferation effect of CCNE2 on human glioma cells. ∗P < 0.05 vs. CCNE2 (+)-NC group; #P < 0.05 vs. CCNE2 (−)-NC group. (B) Flow cytometry analysis of human
glioma cells with the expression of CCNE2 changed. ∗P < 0.05 vs. CCNE2 (+)-NC group; #P < 0.05 vs. CCNE2 (−)-NC group. (C) Quantification of migration and
invasion cells with the expression of CCNE2 changed. Representative images and accompanying statistical plots were presented. ∗P < 0.05 vs. CCNE2 (+)-NC
group; #P < 0.05 vs. CCNE2 (−)-NC group. Scale bars represent 20 µm.
the malignant behaviors of human glioma U87 and U251 cells.
In addition, the KCNQ1OT1 knockdown up-regulated
miR-370, which was lowly expressed in glioma tissues and
cells. CCNE2 is a direct target of miR-370. We found that
CCNE2 was up-regulated in glioma tissues. We further
discovered that miR-370 played a tumor-suppressive role by
down-regulating CCNE2 in glioma cells. The in vivo study
demonstrated knockdown of KCNQ1OT1 combined with
miR-370 over-expression produced the smallest tumor and
the longest survival period in nude mice. Taken together,
the KCNQ1OT1/miR-370/CCNE2 axis might exert an
important role in human glioma tumorigenesis and malignant
progression, which provided a novel promising therapeutic
target.
Many research indicate that lncRNAs are abnormally
expressed in multiple tumors, and play important roles in the
biological processes of tumor cells (Bartonicek et al., 2016;
Serghiou et al., 2016). LncRNA MALAT1 is up-regulated in
pancreatic cancer, epigenetically inducing MALAT1 promotes
tumor cell growth and invasion via regulating autophagy
(Li et al., 2016). LncRNA TUG1 is highly expressed in
hepatoblastoma tissues and cells, silencing TUG1 impairs
cell proliferation, migration and invasion through increasing
miR-34a-5p expression (Dong et al., 2016). KCNQ1OT1 encodes
a paternally expressed long non-coding RNA, which has been
shown to regulate the imprinting of several genes present
at 11p15.5 locus in cis (Bliek et al., 2001; Higashimoto
et al., 2006; Fedoriw et al., 2012; Schultz et al., 2015).
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FIGURE 6 | Sh-KCNQ1OT1 phenotype was reversed by over expression of CCNE2. (A) CCK-8 assay was used to determine the proliferation effect of
sh-KCNQ1OT1 + CCNE2 on human glioma cells. ∗P < 0.05 vs. Control group; #P < 0.05 vs. sh-KCNQ1OT1 group. (B) Flow cytometry analysis of human glioma
cells with the expression of CCNE2 changed. ∗P < 0.05 vs. Control group; #P < 0.05 vs. sh-KCNQ1OT1 group. (C) Quantification of migration and invasion cells
with the expression of CCNE2 changed. Representative images and accompanying statistical plots were presented. ∗P < 0.05 vs. Control group; #P < 0.05 vs.
sh-KCNQ1OT1 group. Scale bars represent 20 µm.
KCNQ1OT1 aberrant expression is ubiquitous in various
cancers. KCNQ1OT1 is up-regulated in Wilms’ tumor
cells. Knockdown of KCNQ1OT1 promotes apoptosis of
Wilms’ tumor cells (Yoshizawa et al., 2015). Consistent with
previously reported, we proved that KCNQ1OT1 was highly
expressed in glioma tissues and cells. Also, epigenetically
silencing KCNQ1OT1 restrained proliferation, migration and
invasion, while promoting apoptosis of glioma cells. Therefore,
KCNQ1OT1 might be an oncogene in glioma and promote
glioma cells’ malignant progression.
MiRNAs have various expression patterns and different
biological functions in tumors. MiR-29a is highly expressed
in breast cancer, and over-expressed miR-29a predicts shorter
survival in patients with breast cancer. Inhibition of miR-29a
impairs cell proliferation and weakens cell migratory abilities via
up-regulating TET1 (Pei et al., 2016). MiR-497-5p exerts tumor-
suppressive function in human angiosarcoma, reintroduction of
miR-497-5p reduces KCa3.1 expression by targeting its mRNA
3′-UTR (Chen et al., 2016). MiR-370 is first identified as a
tumor-suppressor in human cholangiocytes, and is found to
be methylated by Interleukin-6 (Meng et al., 2008). MiR-370
exerts different function in various tumors. In most cases,
miR-370 is lowly expressed and exerts tumor-suppressive role
in tumor cells (Lo et al., 2012; Chen et al., 2014). A latest
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FIGURE 7 | MiR-370 inhibited human glioma cells malignant progression via targeting to CCNE2 3′-UTR. CCNE2 activated the YAP1 signal pathways.
(A) CCK-8 assay was used to evaluate the proliferation effect of miR-370 and CCNE2 changed on human glioma cells at 24 h, 48 h and 72 h. (B) Flow cytometry
analysis of human glioma cells with the expression of miR-370 and CCNE2 changed. (C) Quantification of migration and invasion cells with the expression of
miR-370 and CCNE2 changed. Representative images and accompanying statistical plots were presented. Data are presented as the mean ± SD (n = 5, each
group). ∗#P < 0.05 vs. miR-370 + CCNE2 group. Scale bars represent 20 µm. (D) Western blot analysis of the YES-associated protein (YAP) pathways regulated by
CCNE2 in human glioma cells. Data are presented as the mean ± SD (n = 5, each group). ∗N#P < 0.05 vs. Sh-KCNQ1OT1 group and pre-miR-370 group.
study shows that miR-370 is down-regulated in human glioma
tissues cells (Peng et al., 2016). In addition, it has been
confirmed that miR-370 inhibits glioma cells’ proliferation
via targeting cyclin D1 and c-myc. Therefore, we further
investigated the potential detailed function miR-370 might
exert. As expected, our results showed that overexpression
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FIGURE 8 | In Vivo study. (A) The stable expressing cells were used for the in vivo study. The nude mice carrying tumors from respective groups were shown. The
sample tumor from respective group was shown. (B) Tumor volume was calculated every 4 days after injection, and the tumor was excised after 44 days.
∗P < 0.05 vs. Control group; #P < 0.05 vs. pre-miR370 group; NP < 0.05 vs. sh-KCNQ1OT1 group. (C) The survival curves of nude mice injected into the right
striatum (n = 15). P < 0.05 (pre-miR-370 or sh-KCNQ1OT1 group vs. Control group); P < 0.01 (pre-miR-370 + sh-KCNQ1OT1 group vs. Control group).
of miR-370 restrained glioma cells’ malignant progression,
including cell proliferation, migration and invasion, while
promoting apoptosis.
Recent studies have showed that lncRNAs can function
as endogenous miRNA sponges by sponging miRNAs in a
sequence-specific manner and impairing their function in
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FIGURE 9 | The schematic cartoon of the mechanism of KCNQ1OT1 negatively regulated miR-370/CCNE2 axis in glioma.
a RISC manner. LncRNA NEAT1 promotes non-small cell
lung cancer (NSCLC) cell via decreasing miR-377 expression.
Mechanically, miR-377 targets NEAT1, and NEAT1 and
miR-377 are in a RISC complex (Sun C. et al., 2016).
Similarly, lncRNA MIR31HG harbors two miR-193b binding
sites. MIR31HG and miR-193b respectively regulates each
expression in a RISC manner (Yang et al., 2016). Our results
showed KCNQ1OT1 exerted oncogenic role while miR-370
exerted the opposite function in glioma cells. Bioinformatics
software (Starbase) indicated KCNQ1OT1 might harbor a
binding site of miR-370. Luciferase reporter confirmed the
binding site of miR-370 in KCNQ1OT1, and RIP assays
supported the hypothesis that KCNQ1OT1 and miR-370
were in a RISC complex. Further, KCNQ1OT1 negatively
regulated miR-370, and miR-370 inversely modulated
KCNQ1OT1 expression. Knockdown of KCNQ1OT1 combined
with miR-370 significantly restrained malignant behaviors
of glioma cells in vitro and reduced tumor growth in vivo.
Furthermore, KCNQ1OT1 inhibition combined with miR-370
over-expression significantly decreased CCNE2 and increased
p-YAP expression. These results supported our assumption
that KCNQ1OT1 promoted glioma cells progression via
decreasing miR-370 expression. However, the underlying
mechanism between miR-370 and CCNE2 remained
unclear.
MiRNAs regulate cellular events by binding to the 3′-UTRs
of downstream genes. For example, miR-208a-3p promotes
gastric cancer cell proliferation via targeting PDCD4 3′-UTR
(Yin et al., 2016). Meanwhile, miR-504 exerts tumor-suppressive
function via targeting FOXP1 3′-UTR in glioma (Cui et al.,
2016). In our study, three kinds of bioinformatics softwares
indicated CCNE2 was a target of miR-370. Further, luciferase
reporter results confirmed the binding site between miR-370
and CCNE2. CCNE2 belongs to the G(1) cyclin family and
exerts important role in G1/S transition of the cell cycle
(Payton and Coats, 2002). Dysregulation of CCNE2 has
been reported in various tumors, such as breast cancer
and NSCLC (Matsushita et al., 2015; Ye et al., 2016). In
human prostate cancer, CCNE2 expression is elevated in
tumor tissues (Wu et al., 2009, and when PTEN, which
is conventionally lowly expressed in prostate cancer cells,
is reintroduced, CCNE2 is blocked and results in cycle
G(1) arrest (Macdonald et al., 2014). Moreover, miR-30a
expression is negatively correlated with CCNE2 in prostate
cancer pathological specimens (Zhang et al., 2016b). Similarly,
CCNE2 expression is increased in NSCLC, over-expressed
CCNE2 facilitates NSCLC cell growth and the effect can
be abolished by reintroduction of miR-30d-5p (Chen et al.,
2015). Consistent with previous studies, our results showed
that CCNE2 expression was elevated in glioma tissues.
Inhibition of CCNE2 hindered glioma cells progression.
Also, CCNE2 inversed miR-370-induced suppression on
glioma cells malignant behavior. Besides, a latest study shows
CCNE2 is involved in regulation of Hippo pathway in breast
cancer (Pegoraro et al., 2015). Hippo pathway is characterized
as a tumor-suppressive axis, and plays important roles in
tumor cellular process including proliferation, migration,
invasion, and apoptosis (Alam et al., 2016; Atkins et al.,
2016; Kemppainen et al., 2016; Mao et al., 2016). YAP is an
important transcriptional activator and can be phosphorylated
by Hippo pathway (Bouvier et al., 2016). Phosphorylation of
YAP induces YAP functional nucleus localization transit to
nonfunctional cytoplasmic cell distribution (LaQuaglia et al.,
2016). We have demonstrated that KCNQ1OT1 regulated
CCNE2 expression via decreasing miR-370 expression.
Therefore, phosphorylated YAP expression were detected
in cells treated with KCNQ1OT1 inhibition, miR-370 restoration
and co-transfected KCNQ1OT1 inhibition and miR-370
restoration glioma cells. As expected, phosphorylated YAP
expression was predominantly increased in cells co-transfected
with KCNQ1OT1 inhibition and miR-370 restoration. This may
partially declare the underlyingmechanism of KCNQ1OT1/miR-
370 regulation on glioma cells. The mechanism underlying
tumorgenesis of human glioma cell lines by KCNQ1OT1 is
schematically presented in Figure 9.
In conclusion, our study demonstrated that knockdown of
KCNQ1OT1 inhibited glioma cells malignancy by up-regulating
miR-370. Moreover, miR-370 suppressed glioma cells’ malignant
biological behaviors by targeting CCNE2, and further activated
Hippo pathway. Thus, therapy targeting KCNQ1OT1/miR-
370/CCNE2 axis may be a promising option for the treatment
of human gliomas.
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